EUR-Lex Access to European Union law
This document is an excerpt from the EUR-Lex website
Document 32022R0510
Commission Regulation (EU) 2022/510 of 29 March 2022 amending Council Regulation (EC) No 297/95 as regards the adjustment of the fees of the European Medicines Agency to the inflation rate with effect from 1 April 2022 (Text with EEA relevance)
Commission Regulation (EU) 2022/510 of 29 March 2022 amending Council Regulation (EC) No 297/95 as regards the adjustment of the fees of the European Medicines Agency to the inflation rate with effect from 1 April 2022 (Text with EEA relevance)
Commission Regulation (EU) 2022/510 of 29 March 2022 amending Council Regulation (EC) No 297/95 as regards the adjustment of the fees of the European Medicines Agency to the inflation rate with effect from 1 April 2022 (Text with EEA relevance)
C/2022/1807
OJ L 103, 31.3.2022, p. 3–6
(BG, ES, CS, DA, DE, ET, EL, EN, FR, GA, HR, IT, LV, LT, HU, MT, NL, PL, PT, RO, SK, SL, FI, SV)
In force
31.3.2022 |
EN |
Official Journal of the European Union |
L 103/3 |
COMMISSION REGULATION (EU) 2022/510
of 29 March 2022
amending Council Regulation (EC) No 297/95 as regards the adjustment of the fees of the European Medicines Agency to the inflation rate with effect from 1 April 2022
(Text with EEA relevance)
THE EUROPEAN COMMISSION,
Having regard to the Treaty on the Functioning of the European Union,
Having regard to Council Regulation (EC) No 297/95 of 10 February 1995 on fees payable to the European Agency for the Evaluation of Medicinal Products (1), and in particular Article 12, fifth subparagraph, thereof,
Whereas:
(1) |
In accordance with Article 67(3) of Regulation (EC) No 726/2004 of the European Parliament and of the Council (2), the revenue of the European Medicines Agency consists of a contribution from the Union and fees paid by undertakings to that Agency. Regulation (EC) No 297/95 lays down the categories and levels of such fees. |
(2) |
Those fees should be updated by reference to the inflation rate of 2020 and 2021. The inflation rate in the Union, as published by the Statistical Office of the European Union (3), was 0,3 % in 2020 and 5,3 % in 2021. |
(3) |
For the sake of simplicity, the adjusted levels of the fees should be rounded to the nearest EUR 100. |
(4) |
Regulation (EC) No 297/95 should therefore be amended accordingly. |
(5) |
For reasons of legal certainty, this Regulation should not apply to valid applications which are pending on 1 April 2022. |
(6) |
In accordance with Article 12 of Regulation (EC) No 297/95, the update is to be made with effect from 1 April 2022. It is therefore appropriate that this Regulation enters into force as a matter of urgency and applies from that date, |
HAS ADOPTED THIS REGULATION:
Article 1
Regulation (EC) No 297/95 is amended as follows:
(1) |
Article 3 is amended as follows:
|
(2) |
in Article 4, first subparagraph, ‘EUR 73 800’ is replaced by ‘EUR 77 900’; |
(3) |
Article 5 is amended as follows:
|
(4) |
in Article 6, first subparagraph, ‘EUR 44 400’ is replaced by ‘EUR 46 900’; |
(5) |
Article 7 is amended as follows:
|
(6) |
Article 8 is amended as follows:
|
Article 2
This Regulation shall not apply to valid applications pending on 1 April 2022.
Article 3
This Regulation shall enter into force on the day following that of its publication in the Official Journal of the European Union.
It shall apply from 1 April 2022.
This Regulation shall be binding in its entirety and directly applicable in all Member States.
Done at Brussels, 29 March 2022.
For the Commission
The President
Ursula VON DER LEYEN
(2) Regulation (EC) No 726/2004 of the European Parliament and of the Council of 31 March 2004 laying down Community procedures for the authorisation and supervision of medicinal products for human and veterinary use and establishing a European Medicines Agency (OJ L 136, 30.4.2004, p. 1).
(3) Eurostat, euroindicators 11/2022, published on 20 January 2022